Biofrontera (NASDAQ:BFRI) and Vertex Pharmaceuticals (NASDAQ:VRTX) Critical Analysis

Biofrontera (NASDAQ:BFRI) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, dividends, analyst recommendations, valuation and earnings.

Profitability

This table compares Biofrontera and Vertex Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Biofrontera	-25.26%	-1,236.11%	-56.67%
Vertex Pharmaceuticals	35.51%	23.86%	17.13%

Valuation and Earnings

This table compares Biofrontera and Vertex Pharmaceuticals”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biofrontera	$41.71 million	0.28	-$10.54 million	($1.03)	-0.93
Vertex Pharmaceuticals	$12.00 billion	9.58	$3.95 billion	$16.86	26.87

Vertex Pharmaceuticals has higher revenue and earnings than Biofrontera. Biofrontera is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Biofrontera has a beta of 0.89, meaning that its share price is 11% less volatile than the S&P 500. Comparatively, Vertex Pharmaceuticals has a beta of 0.3, meaning that its share price is 70% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Biofrontera and Vertex Pharmaceuticals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biofrontera	1	0	1	0	2.00
Vertex Pharmaceuticals	0	5	20	1	2.85

Biofrontera currently has a consensus target price of $2.75, indicating a potential upside of 186.52%. Vertex Pharmaceuticals has a consensus target price of $555.17, indicating a potential upside of 22.54%. Given Biofrontera’s higher probable upside, research analysts plainly believe Biofrontera is more favorable than Vertex Pharmaceuticals.

Institutional and Insider Ownership

10.1% of Biofrontera shares are held by institutional investors. Comparatively, 91.0% of Vertex Pharmaceuticals shares are held by institutional investors. 4.8% of Biofrontera shares are held by company insiders. Comparatively, 0.2% of Vertex Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Vertex Pharmaceuticals beats Biofrontera on 12 of the 15 factors compared between the two stocks.

About Biofrontera

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.